echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Ruike Biotechnology completes nearly RMB 1 billion in Series C financing

    Ruike Biotechnology completes nearly RMB 1 billion in Series C financing

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, news came from the industry that Ruike Biotechnology completed a round C financing of approximately RMB 1 billion


    Ruike Biotechnology was formed by the merger of Jiangsu Ruike Biotechnology Co.


    According to the official website of Ruike Biology, the company's product pipeline includes HPV series vaccines, recombinant herpes zoster virus vaccines, tuberculosis vaccines, recombinant new crown vaccines and so on


    Regarding this financing, Dr.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.